https://european-biotechnology.net/wp-content/uploads/2026/02/resource-database-4uUmTpyb5eU-unsplash-1-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-18 16:56:022026-02-18 16:56:02PLL Therapeutics reports positive phase I/II data for gut-targeting ALS therapy
https://european-biotechnology.net/wp-content/uploads/2026/02/v2osk-In4XVKhYaiI-unsplash-1030x658-1.jpg6581030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-18 15:27:202026-02-18 15:27:20Axol buys Newcells’ ophthalmology business to grow drug discovery portfolio
https://european-biotechnology.net/wp-content/uploads/2026/02/igor-omilaev-t4dYnNOUOWc-unsplash-2-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-18 09:09:102026-02-18 09:09:10Compass Pathways clears second phase III hurdle for psilocybin in treatment-resistant depression
https://european-biotechnology.net/wp-content/uploads/2026/02/george-c-awmdBIp6IO4-unsplash-2-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-17 13:08:532026-02-17 13:08:53Newron secured €38m to test a potential new class in schizophrenia
https://european-biotechnology.net/wp-content/uploads/2026/02/zyanya-citlalli-wBRYgdB3qIs-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-17 12:32:212026-02-17 12:32:21Biotech Beactica and research institute LISCO secured €2.5M to advance glioblastoma therapy to the clinic
